Abstract
The attempts to increase novel drug productivity through creative discovery technologies have fallen short of producing the satisfactory results. For these reasons, evolved from the concept of drug repositioning, “privileged structure”-guided scaffold re-evolution/refining is a primary strategy to identify structurally novel chemotypes by modifying the central core structure and the side-chain of the existing active compounds, or to exploit undescribed bioactivites by making full use of readily derivatized motifs with well-established synthetic protocols. Herein, we review the basic tricks of exploiting privileged structures for scaffold re-evolution/refining. The power of this strategy is exemplified in the discovery of other new therapeutic applications by refining privileged structures in anti-viral agents.
Keywords: Drug design, drug repositioning, privileged structure, scaffold re-evolution, scaffold refining.
Combinatorial Chemistry & High Throughput Screening
Title:"Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining
Volume: 17 Issue: 6
Author(s): Yu'ning Song, Wenmin Chen, Dongwei Kang, Qingzhu Zhang, Peng Zhan and Xinyong Liu
Affiliation:
Keywords: Drug design, drug repositioning, privileged structure, scaffold re-evolution, scaffold refining.
Abstract: The attempts to increase novel drug productivity through creative discovery technologies have fallen short of producing the satisfactory results. For these reasons, evolved from the concept of drug repositioning, “privileged structure”-guided scaffold re-evolution/refining is a primary strategy to identify structurally novel chemotypes by modifying the central core structure and the side-chain of the existing active compounds, or to exploit undescribed bioactivites by making full use of readily derivatized motifs with well-established synthetic protocols. Herein, we review the basic tricks of exploiting privileged structures for scaffold re-evolution/refining. The power of this strategy is exemplified in the discovery of other new therapeutic applications by refining privileged structures in anti-viral agents.
Export Options
About this article
Cite this article as:
Song Yu'ning, Chen Wenmin, Kang Dongwei, Zhang Qingzhu, Zhan Peng and Liu Xinyong, "Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining, Combinatorial Chemistry & High Throughput Screening 2014; 17 (6) . https://dx.doi.org/10.2174/1386207317666140122101631
DOI https://dx.doi.org/10.2174/1386207317666140122101631 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Pediatric Mediastinal Masses and Castlemans Disease
Current Pediatric Reviews Targeted Tumor Therapies at a Glance
Current Drug Targets Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets ACE2 and Diabetic Complications
Current Pharmaceutical Design Multimodal HDAC Inhibitors with Improved Anticancer Activity
Current Cancer Drug Targets Homology Modeling and Docking Studies of Bcl-2 and Bcl-xL with Small Molecule Inhibitors: Identification and Functional Studies
Current Topics in Medicinal Chemistry Nanoparticle-Based Combination Therapy for Cancer Treatment
Current Pharmaceutical Design Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Self-Renewal Versus Differentiation in Hematopoietic Stem and Progenitor Cells: A Focus on Asymmetric Cell Divisions
Current Stem Cell Research & Therapy Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology How to Manage the Risk of Colorectal Cancer in Ulcerative Colitis
Current Drug Targets Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Modelling and Measuring Redox Cycling and Cytotoxicity of Quinones
Drug Metabolism Letters Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design 1-O-Octadecyl-2-O-Methylglycero-3-phosphocholine (Edelfosine) and Cancer Cell Invasion: A Short Review
Anti-Cancer Agents in Medicinal Chemistry